Drug intelligence / Profile preview

GF11

Development stage: Preclinical
Lead developer: Hangzhou Jinshennuo Biopharmaceutical
Modality: Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Small Molecules
Administration: Intravenous

Overview

**GF11** is an intravenous liposomal formulation of the taxane chemotherapy agent **docetaxel**, developed by Xiamen Ginposome Pharmaceutical. The product uses a ginsenoside-based liposomal carrier to deliver docetaxel. Docetaxel binds tubulin and stabilizes microtubules, disrupting normal mitotic spindle dynamics and causing cell-cycle arrest and tumor-cell death. GF11 has been listed in the developer's pipeline for breast cancer, non-small cell lung cancer, and gastric cancer, with an NDA/BLA-stage development designation.

Other names: Docetaxel Ginsenoside Liposome Injection注射用复方多西他赛人参皂苷脂质体

Targets

TUBB (Tubulin (alpha and beta subunits))

Beyond the preview

Go deeper on GF11.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GF11.

Explore the full profile